Loading
MightyTIL is an experimental cell treatment from TrAMPoline Pharma that strengthens immune cells taken from a patient's own tumour. It is in laboratory testing.
MightyTIL is the lead candidate of TrAMPoline Pharma, an autologous gene-engineered TIL product for sarcoma, head and neck cancer and melanoma. The company reports higher potency, persistence and lower IL-2 needs than unmodified TIL in preclinical studies. No clinical data exist.
Tumour-infiltrating lymphocytes engineered with coR8:Amp, which the developer says strengthens T cell receptor binding to cancer cells and T cell receptor signalling.
1.MightyTIL slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MightyTIL" OR ABSTRACT:"MightyTIL" OR TITLE:"MightyTIL TrAMPoline Pharma" OR ABSTRACT:"MightyTIL TrAMPoline Pharma") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MightyTIL, not a curated reading list.
Shares TIL therapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/